Abstract Body

Opioid use disorder (OUD) and injection drug use (IDU) behavior are both highly prevalent among justice involved individuals, with the latter increasing risk for HIV acquisition. Medications for opioid use disorder (MOUD), including extended-release naltrexone (XR-NTX), are associated with increased retention on antiretroviral therapy (ART) and viral suppression in persons with HIV (PWH). However, the effect of XR-NTX on IDU risk behavior is incompletely studied. This relationship was examined in justice involved individuals with HIV and OUD. We hypothesized that XR-NTX would reduce IDU risk behavior following release from prison or jail.

A secondary analysis was performed of data obtained from a NIDA-funded double-blind placebo controlled randomized trial of persons in prison and jail with HIV and OUD who were randomized 2:1 to receive either monthly XR-NTX or placebo prior to release with 5 more subsequent injections in the community post-release. Participants were assessed monthly and data was collected on self-reported daily IDU pre-incarceration as well as monthly post-incarceration for 6 months via the timeline follow back technique. Time to first opioid injection and number of consecutive days abstinent from injection were analyzed. Mean proportion of monthly opioid use was calculated and a time to event analysis was performed.

A total of 88 individuals were included for this analysis with 62 receiving XR-NTX and 26 placebo. The mean age of participants was 45.7 years and both groups were predominately male, black, and Hispanic. Seventy four (84.1%) were prescribed ART, 51 (57.9%) had an HIV RNA < 200 copies/mL at baseline and 62 (70.5%) were HCV antibody positive. There was no difference in IDU risk behaviors in the intention to treat analysis, however the as treated analysis for those who received 3 or more injections of XR-NTX had significantly lower mean proportion of IDU days by month 5 of follow-up (0.04 vs 0.26, p<0.05) and had a longer time to IDU relapse (Mean=136.4 vs 53.2 days, p=0.002) versus placebo. There was no difference after month 6 of follow-up when the parent study intervention ceased.

In this cohort of justice involved PWH and OUD, XR-NTX was associated with reduced IDU risk behavior and a longer time to IDU relapse. Our results suggest that integration of MOUD with HIV treatment can reduce IDU risk behavior. Further public health efforts are warranted to promote harm reduction via uptake and maintenance of MOUD in PWH with OUD.